Abstract
Backgrounds and objectives: Due to the high incidence of collateral effects NSAID-associated, the discovery of two cyclooxygenase isoforms, classified as: COX-1 or constitutive and COX-2 or inductive, formulated the paradigm that the anti-inflammatory properties of NSAID would be mediated by COX-2 inhibition, and the adverse effects, by the block of COX-1. However, COX-2 has been detected constitutively in normal tissues and, uncertainties have emerged about the real safe profile of the specific COX-2 inhibitors. The aim of this review is to report new clinical and experimental evidences involving COX-2 isoenzyme and its specific inhibitors. Contents: New concepts about structural differences between COX-1 and 2, the existence of these isoforms in different organic tissues and experiments in animal and humans are reported, besides clinical observations of specific COX-2 inhibitors agents. Conclusion: Coxibs represent important pharmacological advance for the antiiflammatory treatment, reducing serious gastrintestinal adverse effects, and probably playing a role in the prevention of cancer and neurologic diseases. However, undistinguished collateral effects from conventional NSAIDs have still persisted, and they are expensive drugs. Like all new medication, careful surveillance and future large-scale outcome analyses will be requisite to determine their ultimate benefit and safety profile

Key words
Ciclooxigenase, anti-inflamatórios não esteróides

Bibliografía del artículo

1. Dubois R, Abramson S, Crofford L, et al - Cyclooxigenase in biology and disease. Faseb J. 1998; 12: 1063-1088,.
2. Tilley Sl, Coffman, TM, Koller BH - Mixed messages modulation of inflammation and immune responses by prostaglandins and thromboxanes. J Clin Invest, 2001; 108: 15-23.
3. Gottschalk A, Smith DS - New concepts in acute pain therapy: Preemptive analgesia. Am Fam Physician, 2001; 63:1979-1984
4. Vane JR - Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature, 1971;231: 232-235.
5. Dahl V, Aeder JC - Non-opioid postoperative analgesia. Acta Anaesth Scand, 2000; 44(10): 1191-203.
6. Yaksh TL, Dirig DM, Conway CM et al - The acute antihyperalgesic action of nonsteroidal, anti-inflammatory drugs and release of spinal prostaglandin E2 is mediated by the inhibition of constitutive spinal cyclooxygenase-2 (COX-2) but not COX-1, Journal of Neuroscience. 2001; 21: 5847-5853.
7. Souter AJ, Fredman B, White PF - Controversies in the perioperative use of nonsteroidal antiinflamatory drugs. Anesth Analg, 1994; 79: 1178-1190.
8. Perazella MA, Tray K - Selective cyclooxygenase-2 inhibitors: A pattern of nephrotoxicity similar to traditional nosteroidal anti-inflammatory drugs. Am J Med, 2001; 111: 64-67.
9. Brooks P, Emery E, Evans F et al - Interpreting the clinical significance of the diferential inhibition of cyclooxygenase-1 and cyclooxygenase-2. Rheumatology, 1999; 38: 779-788.
10. Marnett LJ, Rowlinson Ws, Goodwin DC, et al. Arachidonic acid oxygenation by COX-1 and COX-2 - J Biol Chem, 1999; 274: 22903-22906.
11. Jones R - Nonsteroidal Anti-inflamatory drug prescribing: Past, present and future. Am J Med, 2001; 110:4s-7s.
12. Fitzgerald GA, Patrono C - The coxibs, selective inhibitor of cyclooxygenase-2. N Engl J Méd, 200; 345: 433-442,
13. Harris RC, Breyer MD - Physiological regulation of cyclooxygenase-2 in the kidney. Am J Physiol Renal Physiol, 2001; 281: F1-F11.
14. Schonbeck U, Sukhova GK, Graber P, et al. - Augmented expression of COX-2 in human atherosclerotic lesions. Am J Pathol, 1999; 155: 1281-91.
15. Reddy ST, Herschman HR -Transcellular prostaglandin production following mast cell activation is mediated by proximal secretory phospholipase A2 and distal prostaglandin synthase-1. J Biol Chem, 1996; 271: 186-91,
16. Lipsky PE et al - Unresolved issues in the role of cyclooxygenase-2 in normal physiologic processes and disease. Arch Intern Med, 2000; 160: 913-920.
17. Beejay V, Wolfe M M - Cyclooxygenase 2 selective inhibitors: Panacea or flash in the pan Gastroenterology, 1999; 117: 1002-1005.
18. Willoughby DA, Moore AR, Colville-Nash PR - COX-1, COX-2, and COX-3 and the future of chronic inflammatory disease. Lancet, 2000; 355: 646-648.
19. Pairet M, Van Ryn J - Experimental models used to investigate the diferential inhibition of cyclooxygenase-1 and cyclooxygenase-2 by non-steroidal anti-inflammatory drugs. Inflamm Res, 1998; 47:s93-s101.
20. Whelton A - Renal aspects of treatment with conventional nonsteroidal anti-inflammatory drugs versus cyclooxygenase-2 specifec inhibitors. Am J Med, 2001, 110: 33s-42s.
21. Chan CC, Boyce S, Brideau C et al - Rofecoxib [VIOXX, MK-0966,4- (4´methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor-pharmacological and biochemical profiles. J Pharmacol Exp Ther, 1999; 290: 551-560.
22. Cannon Gw, Breedveld FC - Efficacy of cyclooxygenase-2 specific inhibitors. Am J Med, 2001; 110: 6s-12s.
23. Jain KK - Evaluation of intravenous parecoxib for the relief of acute post-surgical pain. Expert Opin Investig Drugs, 2000; 9(11):2717-23
24. Cheer SM, Goa KL - Parecoxib (parecoxib sodium). Drugs, 2001; 61 (8): 1133-41
25. Lee A, Cooper MG, Craig JC, Knight JF, Keneally JP - Effects of nonsteroidal anti-inflammatory drugs on post-operative renal function in adults. Cochrane Database Syst Rev, 2000; (4): CD002765
26. Harris CJ, Brater DC - Renal effects of cyclooxygenase 2 selective inhibitors. Curr Opin Nephrol Hypertens 2001 Sep; 10(5): 603-610.
27. Wang JL, Cheng HF, Harris RC - Cyclooxygenase inhibition decreases rennin content and lowers blood pressure in a model of renovascular hypertension. Hypertension, 1999; 34: 96-101.
28. Wolf K, Castrop H, Hartner A et al - Inhibition of the rennin-angiotensin system upregulates cyclooxygenase-2 expression in the macula densa. Hypertension, 1999; 34: 503-507.
29. Yang T, Schnermann JB, Briggs JP - Regulation of cycloooxygenase-2 expression in renal medulla by tonicity in vivo and in vitro. Am J Physiol Renal Physiol, 1999; 277: F1-F9.
30. Hao CM, Yull F, Blackwell T et al - Dehydration activates an NF-kB-driven, COX-2 dependent survival mechanism in renal medullary intesticial cells. J Clin Invest, 2000; 106: 973-982.
31. Cowley A, Mattson D, Lu S, Roman R -The renal medulla and hypertension. Hypertension, 1995; 25: 663-673.
32. Brater DC - Effects of nonsteroidal anti-inflammatory drugs on renal function: focus on cyclooxygenase-2 inhibition. Am J Med, 1999; 107:65s-70s.
33. Komhoff M, Wang JL, Cheng HF et al - Cyclooxygenase-2 selective inhibitors impair glomerulogenesis and renal cortical development. Kidney Int, 2000; 57: 414-22.
34. Nantel F, Meadows E, Denis D et al - Immunolocalization of cyclooxygenase-2 in the macula densa of human elderly. FEBS letters; 1999, 457:475-477.
35. Rocha JL, Férnandez-Alonso J - Acute tubulointersticial nephritis associated with the selective COX2 enzyme inhibitor, rofecoxib. Lancet, 2001; 357: 1946-1947.
36. Buttgereit F, Burmester GR, Simon LS - Gastrointestinal toxic side effects of nonsteroidal antiiflammatory drugs and cyclooxygenase-2 specific inhibitors. Am J Med, 2001; 110: 13s-19s.
37. Emery P - Cyclooxygenase-2: A major therapeutic advance Am J Med, 2001; 110: 42s-45s.
38. Eckmann L, Stenson C, Matsuda K et al - Induction of intestinal epithelial cells in the host secretory response to infection by invasive bacteria: bacterial entry induces epithelial prostaglandin H synthase-2 expression and prostaglandin E2 and F2 production. J Clin Invest, 1997; 100: 269-309.
39. Schnitzer Tj. Cyclooxygenase-2 specific inhibitors - Are they safe Am J Med, 2001; 110: 46s-49s.
40. Patrono C - Aspirin as an antiplatelet drug. N Eng J Med, 1994; 330: 1287-1294.
41. Rodriguez -Tellez M, Arguelles F, Herrerias Jm, Ledro JD - Antiiniflammatory Agents Less Dangerous for Gastointestinal Tract. Current Pharm Des, 2001; 7: 951-976.
42. Yeomans ND - New data on healing of nonsteroidal anti-inflammatory drug associated ulcers and erosion: Omeprazole NSAID steering committee. Am J Med, 1998; 104: 56s-61s.
43. O´Beirne JP, Cairns SR - Cholestatic hepatitis in association with celecoxib. Br Med J, 2001; 323:23.44-
44. Maddrey WC, Maurath CJ, Verburg KM, Geis GS - The hepatic safety and tolerability of the novel cyclooxygenase inhibitor celecoxib. Am J Ther, 2000; 7: 153-158.
45. Carillo-Jimenez R, Nurnberger M - Celecoxib-induced acute pancreatitis and hepatitis. Arch Intern Med, 2000; 170: 553-554
46. Knowles S, Shapiro L, Shear NH - Should celecoxib be contraindicated in patients who are allergic to sulfonamides Revisiting the meaning of "sulfa" allergy. Drug Saf, 2001; 24: 239-247.
47. Catella-Lawson F, Crofford L J - Cyclooxygenase inhibition and thrombogenicity. Am J Med, 2001; 110: 28s-32s.
48. Wijeyaratne SM, Abbott CR, Homer-Vanniasinkam S et al.- Differences in the detection of cyclo-oxygenase 1 and 2 proteins in symptomatic and asymptomatic carotid plaques. Br J Surg, 2001; 88: 951-957
49. Hawkey CJ, Lanas AI - Doubt and certainty about NSAID in the year 2000: A multidisciplinary expert statement. Am J Med, 2001; 110: 79s-100s.
50. Lipsky PE - Recommendations for the clinical use of cyclooxygenase-2-specific inhibitors. Am J Med, 2001; 110: 3s-5s.
51. Boers M - NSAIDS and COX-2 inhibitors: competition between gastroprotection and cardioprotection. Lancet, 2001: 357: 1222-1223.
52. Karplus TM, Saag KG - Nonsteroidal anti-inflammatory drugs and cognitive function: have a beneficial or deleterious effect Drug Saf, 1998; 19: 427-433
53. Norwitz ER, Robinson JN, Challis JR - The control of labor. N Engl J Med, 1999; 341: 660-6.
54. Sawdy R, Slater D, Fisk N, Edmonds DK et al. - Use of a cycoloxygenase type -2 selective non-steroidal anti-inflammatory agent to preent preterm delivery. Lancet, 1997; 350: 265-266.
55. Peruzzi L, Glanogllo B, Porcellinni MG et al. - Neonatal end-stage renal failure associated with maternal ingestion of COX-2 selective inhibitor nimesulide as tocolytic. Lancet, 1999; 354(9190): 1615.
56. Sjodahl R - Extent, mode and dose dependence of anticancer effects. Am J Med, 2001; 110: 66S-69S.
57. Myers C, Koki A, Pamukcu R et al - Proapoptotic anti-inflammatory drugs. Urology, 2001; 57: 73S-75S
58. Khan KN, Masferrer Jl, Woerner BM et al - Enhanced cyclooxygenase-2 expression in sporadic and familial adenomatous polyposis of the human colon. Scan J Gastroenterol, 2001; 36: 865-869.
59. Steibach G, Lynch PM, Phillips R et al - Effect of celecoxib on colorectal polyposis (FAP). Am J Gastroenterol, 1999; 94: A440.